Tenon Medical Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows from Operating Activities | ||
| Net loss | $(10,586) | $(12,447) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,962 | 3,164 |
| Depreciation and amortization | 291 | 106 |
| Provision for losses on accounts receivable | 46 | — |
| Amortization of operating right-of-use asset | 183 | 169 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | (404) | (545) |
| Inventory | (53) | (59) |
| Prepaid expenses and other assets | (154) | (257) |
| Accounts payable | 660 | 213 |
| Accrued expenses | 143 | (81) |
| Operating lease liability | (189) | (168) |
| Net cash used in operating activities | (7,101) | (9,905) |
| Cash Flows from Investing Activities | ||
| Sales of short-term investments | — | 6,996 |
| Purchases of short-term investments | — | (493) |
| Purchases of property and equipment | (223) | (269) |
| Net cash (used in) provided by investing activities | (223) | 6,234 |
| Cash Flows from Financing Activities | ||
| Proceeds from issuance of Series A convertible preferred stock, net | 2,437 | — |
| Proceeds from issuance of Series B convertible preferred stock, net | 489 | — |
| Proceeds from issuance of common stock, prefunded warrants, and warrants, net | 3,862 | — |
| Proceeds from exercise of warrants under inducement agreement, net | 4,306 | — |
| Proceeds from issuance of common stock, net | 2,106 | 453 |
| Proceeds from issuance of common stock upon exercise of warrants | 812 | — |
| Proceeds from issuance of common stock and warrants, net of issuance costs | — | 4,808 |
| Deferred offering costs | — | (330) |
| Net cash provided by financing activities | 14,012 | 4,931 |
| Effect of foreign currency translation on cash flow | 46 | (18) |
| Net Increase in Cash and Cash Equivalents | 6,734 | 1,242 |
| Cash and Cash Equivalents at Beginning of Period | 2,428 | 2,129 |
| Cash and Cash Equivalents at End of Period | $9,162 | $3,371 |
| Supplemental Disclosures of Cash Flow Information | ||
| Non-cash investing and financing activities: | ||
| Preferred stock issued upon conversion of debt and accrued interest, net of unamortized debt issuance costs | $1,186 | — |
| Reclassification of deferred offering costs to additional paid-in capital | $238 | — |
| Warrant modification costs | $992 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.